drugset / Trial / NCT00141089

Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.

NCT00141089

Phase 3 Completed 1026 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

Tegaserod (HTF919) is an aminoguanidine indole compound and a member of a class of subgroup-selective 5-hydroxytryptamine (5-HT) agonists. The aim of this study was to evaluate the efficacy and safety of tegaserod on bowel habits in male patients with chronic constipation.

Timeline

Start
2004-03
Primary completion
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegaserod Small molecule

Indications